secondary findings
The American College of Medical Genetics and Genomics (ACMG) have identified mutations that are of sufficient risk to patient health that laboratories have been advised to report out these ‘secondary’ findings even if analysis of these specific genes were not the initial indication for genetic testing. Examples include known or expected pathogenic variants in genes related to Marfan syndrome gene (FBN1) associated with risk of aortic dissection and Breast Ovarian Cancer Syndrome (BRCA1 and BRCA2).
